CA2697370A1 - Hiv env proteins with modifications in the v3 loop - Google Patents

Hiv env proteins with modifications in the v3 loop Download PDF

Info

Publication number
CA2697370A1
CA2697370A1 CA2697370A CA2697370A CA2697370A1 CA 2697370 A1 CA2697370 A1 CA 2697370A1 CA 2697370 A CA2697370 A CA 2697370A CA 2697370 A CA2697370 A CA 2697370A CA 2697370 A1 CA2697370 A1 CA 2697370A1
Authority
CA
Canada
Prior art keywords
polypeptide
env
loop
hiv
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2697370A
Other languages
English (en)
French (fr)
Inventor
Susan W. Barnett
Ying Lian
Victoria Sharma
Indresh K. Srivastava
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2697370A1 publication Critical patent/CA2697370A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/21Retroviridae, e.g. equine infectious anemia virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/16011Human Immunodeficiency Virus, HIV
    • C12N2740/16111Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/16011Human Immunodeficiency Virus, HIV
    • C12N2740/16111Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
CA2697370A 2007-08-24 2008-08-25 Hiv env proteins with modifications in the v3 loop Abandoned CA2697370A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US96604807P 2007-08-24 2007-08-24
US60/966,048 2007-08-24
PCT/US2008/074179 WO2009029569A1 (en) 2007-08-24 2008-08-25 Hiv env proteins with modifications in the v3 loop

Publications (1)

Publication Number Publication Date
CA2697370A1 true CA2697370A1 (en) 2009-03-05

Family

ID=39884817

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2697370A Abandoned CA2697370A1 (en) 2007-08-24 2008-08-25 Hiv env proteins with modifications in the v3 loop

Country Status (5)

Country Link
EP (1) EP2192918A1 (pt)
JP (1) JP2010536885A (pt)
BR (1) BRPI0815743A2 (pt)
CA (1) CA2697370A1 (pt)
WO (1) WO2009029569A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201407995RA (en) * 2012-06-18 2015-01-29 Novartis Ag Stabilized gp120

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK116294A3 (en) * 1992-04-01 1996-11-06 Merck & Co Inc Recombinant human hiv-antibodies, cassette for expression, host cell and pharmaceutical agent against hiv
US6710173B1 (en) * 1999-06-25 2004-03-23 Progenics Pharmaceuticals, Inc. Stabilized viral envelope proteins and uses thereof
AU1075001A (en) * 1999-10-05 2001-05-10 Epimmune, Inc. Inducing cellular immune responses to human immunodeficiency virus-1 using peptide and nucleic acid compositions
CA2357906A1 (en) * 2001-09-28 2003-03-28 Institut Pasteur Identification of new cd8 epitopes from hiv-1 proteins with therapeutical and vaccinal properties against hiv infections
AU2003241103A1 (en) * 2002-04-23 2003-11-10 Umberto Dianzani Compositions containing anti-hiv peptides and methods of use
GB0405480D0 (en) * 2004-03-11 2004-04-21 Istituto Superiore Di Sanito Novel tat complexes,and vaccines comprising them

Also Published As

Publication number Publication date
BRPI0815743A2 (pt) 2015-02-18
JP2010536885A (ja) 2010-12-02
EP2192918A1 (en) 2010-06-09
WO2009029569A1 (en) 2009-03-05

Similar Documents

Publication Publication Date Title
US8936789B2 (en) Immunoenhancer-linked oligomeric HIV envelope peptides
US8790898B2 (en) Synthetic peptides corresponding to overlapping neutralizing determinants in the CBD1 epitope induce broadly neutralizing antibodies
CA2942450A1 (en) Mutant staphylococcal antigens
DK2464658T3 (en) Detoxified escherichia coli immunogens
US20080300385A1 (en) Covalently-linked complexes of HIV Tat and Env proteins
CA2697370A1 (en) Hiv env proteins with modifications in the v3 loop
PT99063B (pt) Processo para a producao de uma glicoproteina e de vacinas que a contem
JP2015512394A (ja) Hiv−1gp41プレヘアピン中間体の安定なペプチド模倣体
EP2019686B1 (en) Combined mucosal and parenteral immunization against hiv
CA2750067C (en) Splitting gp41
AU2007249937B2 (en) HIV-1 immunogenic compositions
CA2750058C (en) Novel gp41 antigens
AU2010210071B2 (en) Novel gp41 antigens
Sellhorn et al. JVI Accepts, published online ahead of print on 26 October 2011
AU2013203188A1 (en) Detoxified Escherichia coli immunogens

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20130826

FZDE Discontinued

Effective date: 20150825